Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?
Author(s): Ozal E, Kuralay E, Bingol H, Cingoz F, Ceylan S, Tatar H Affiliation(s): Cardiovascular Surgery Department, Gulhane Military Medical Academy, Etlik, Ankara, Turkey 06010. ozal@tr.net Publication date & source: 2002-03, J Thorac Cardiovasc Surg., 123(3):539-43. Publication type: Clinical Trial; Randomized Controlled Trial OBJECTIVE: Desmopressin releases tissue-type plasminogen activator, which augments cardiopulmonary bypass–associated hyperfibrinolysis, causing excessive bleeding. Combined use of desmopressin with prior administration of the antifibrinolytic drug tranexamic acid may decrease fibrinolytic activity and might improve postoperative hemostasis. METHODS: This prospective randomized study was carried out with 100 patients undergoing coronary artery bypass operations between April 1999 and November 2000 in Gulhane Military Medical Academy. Patients were divided into 2 groups. Desmopressin (0.3 microg/kg) was administrated just after cardiopulmonary bypass and afte
